Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.


Genetic and Rare Diseases Information Center (GARD)

Print friendly version

Multicentric reticulohistiocytosis

See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.


Newline Maker

How might multicentric reticulohistiocytosis be treated?

Dermatologists and rheumatologists are often the types of specialists that oversee the treatment of patients with multicentric reticulohistiocytosis. Although no specific therapy has consistently been shown to improve multicentric reticulohistiocytosis, many different drugs have been used.[1] For instance, therapy with non-steroidal anti-inflammatory agents (e.g., aspirin or ibuprofen) may help the arthritis. Systemic corticosteroids and/or cytotoxic agents, particularly cyclophosphamide, chlorambucil, or methotrexate, may affect the inflammatory response, prevent further joint destruction, and cause skin lesions to regress. Antimalarials (e.g., hydroxychloroquine and mefloquine) have also been used. Alendronate and other bisphosphonates have been reported to be effective in at least one patient and etanercept and infliximab have been effective in some.[2]
Last updated: 6/21/2013

  1. Rapini RP, Morgan LT. Dermatologic Manifestations of Multicentric Reticulohistiocytosis . Medscape Reference . June 6, 2012; Accessed 9/28/2012.
  2. Callen JP. Multicentric Reticulohistiocytosis. Medscape Reference. August 16, 2011; Accessed 9/28/2012.